Nasdaq atai.

Atai Life Sciences (NASDAQ:ATAI) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.

Nasdaq atai. Things To Know About Nasdaq atai.

To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.“In just four years with Florian as CEO we raised more than $600 million, grew the staff to more than 100, brought eight compounds into clinical-stage trials, and took Atai public on the Nasdaq ...NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...

Ticker Symbol: ATAI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $15.00: CIK Code: 0001840904: CUSIP Number: N0731H103 ...Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 ...BEIJING, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ATA Inc. ("ATA" or the "Company", Nasdaq: ATAI), a company focused on providing students with quality educational experiences and services in China and ...

Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Clinical-stage biotech DemeRx, which is part of Atai Life Sciences’ (NASDAQ:ATAI) portfolio, has completed phase 1 trials for noribogaine and is now planning to launch a phase 2 trial on a ...ATAI Life Sciences N.V. Common Shares ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.Here are our picks for the five psychedelic companies to watch in 2022: Atai Life Sciences, Berlin, Germany – listed on NASDAQ (ATAI) since July, 2021 – Market cap $999 million. Atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is also one of the largest shareholders ...(NASDAQ: ATAI) Atai Life Sciences Nv's forecast annual revenue growth rate of 69.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.63%.

Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.

Atai Life Sciences (NASDAQ:ATAI) has a somewhat unique business model, a decentralized platform that acquires and operates clinical programs that are separate companies or behave like them.

Shares of Atai Life Sciences B.V. (ATAI.O), backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market ...Nov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions. Mar 31, 2023 · In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. ... NASDAQ: ATAI Atai Life Sciences. Market Cap. $173M. Today's Change (-7.14% ... ATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and Forecast benzinga.com - August 13 at 4:19 AM: ATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest Report benzinga.com - August 12 at 11:19 PM: ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank markets.businessinsider.com - August 11 at 5:09 PMMar 31, 2023 · In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. ... NASDAQ: ATAI Atai Life Sciences. Market Cap. $173M. Today's Change (-7.14% ... Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates. “As the burden of unmet medical needs in mental health care continues to grow, our team remains …Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7. Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders.Nov 15, 2021 · The atai Impact program will be initially funded by 1% of the gross proceeds from our June 2021 IPO and founders’ and shareholders’ contributions. Third Quarter 2021 Financial Results. Cash ... NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...ATAI Life Sciences N.V. Common Shares (ATAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

May 25, 2023 · ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...

Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds.The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...After seeing a close friend suffer from mental health issues and then self-treating successfully with psychedelics, Florian Brand, the founder of Atai Life Sciences N.V. (NASDAQ:ATAI), realized ...The clinical-stage biopharmaceutical company atai Life Sciences N.V. (NASDAQ: ATAI), which aims to revolutionize the treatment of mental health disorders, ...Atai Life Sciences (NASDAQ:ATAI) has a recorded annual revenue of $230,000.00. How much profit does Atai Life Sciences generate each year? Atai Life Sciences (NASDAQ:ATAI) has a recorded net income of -$152.38 million.Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers ...Atai Life Sciences B.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the pricing of its upsized ...

Atai Life Sciences N.V. (ATAI) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Add to watchlist. 1.0900 +0.0200 (+1.87%) At close: 04:00PM EST. 1.1200 +0.03 …

Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers ...

Atai Life Sciences (Nasdaq: ATAI) Always at the top of the list of psychedelics companies on the move, Atai Life Sciences launched a Phase 1 study of an MDMA derivative focusing on post-traumatic stress disorder in September.One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ... Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired …Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.Company Description. ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive …The average one-year price target for ATAI Life Sciences N.V. (NASDAQ:ATAI) has been revised to 12.57 / share. This is an increase of 5.04% from the prior estimate of 11.97 dated August 31, 2023.The financial services firm H.C. Wainwright & Co. recently issued a $20 price target on ATAI Life Sciences (ATAI 7.69%) stock. This 12-month price target implies an upside potential of 969% from ...ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders.The company has recently garnered ...Apr 13, 2023 · NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.. In numbers: Cash, cash ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...

Nov 17, 2023 · Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ... A high-level overview of Atai Life Sciences N.V. (ATAI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders.The company has recently garnered ...Instagram:https://instagram. etf home buildersvodafone usbud stoclups futures The atai Impact program will be initially funded by 1% of the gross proceeds from our June 2021 IPO and founders’ and shareholders’ contributions. Third Quarter 2021 Financial Results. Cash ... best mortgage loans for rental propertyprincipal 401k withdrawal phone number Aug 8, 2023 · NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... schwab share price Back to ATAI Overview. Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is ...Benzinga. Sep. 27, 2022, 02:04 PM. Atai Life Sciences' (NASDAQ:ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC ...